[c09aa8]: / clusters / final9knumclusters / clust_1647.txt

Download this file

122 lines (121 with data), 8.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
Left ventricular ejection fraction < 50%
Subject must have a left ventricular ejection fraction of ? 50%;
Left ventricular ejection fraction greater than or equal to (>=) 50 percentage (%); >=55% (cohort E only)
Left ventricular ejection fraction >= 50%
Left ventricular ejection fraction > 50%.
Left ventricular ejection fraction of < 45%
Left ventricular ejection fraction < 40%
Participant has left ventricular ejection fraction at rest ? 40%.
Subject has a documented left ventricular ejection fraction > 50%
Cardiac: left ventricular ejection fraction at rest must be ? 45%
Left ventricular ejection fraction < 40%, symptomatic coronary artery disease, or uncontrolled arrhythmias
Left ventricular ejection fraction > 50%
Left ventricular ejection fraction >= 40%.
Left ventricular ejection fraction of at least 45% by either echocardiography or radionucleotide angiography
Must have left ventricular ejection fraction > 50%
Left ventricular ejection fraction >= 50%.
Decreased cardiac function as evidenced by a left ventricular ejection fraction of < 45%
Cardiac: left ventricular ejection fraction < 35%
Left ventricular ejection fraction > 40%
Left ventricular ejection fraction > 30%
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction of > 40%.
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction >= 35%
Cardiac left ventricular ejection fraction >= 50% at rest
Left ventricular ejection fraction >= 50%
Must have left ventricular ejection fraction >= 50%
Must have left ventricular ejection fraction > 50%
Left ventricular ejection fraction >= 40%
Left ventricular ejection fraction < 50%
Left ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)
Left ventricular ejection fraction >= 40%
Adequate cardiac function with a left ventricular ejection fraction >= 40%
Adequate cardiac function with left ventricular ejection fraction >= 40%
Systolic heart failure defined as left ventricular ejection fraction =< 45%
Adequate cardiac function with left ventricular ejection fraction >= 40%
The subject has a documented left ventricular ejection fraction > 50%
Left ventricular ejection fraction ? 45%
Left ventricular ejection fraction > 45%
PART 2: Left ventricular ejection fraction > 40% OR
Patients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled arrhythmia); if the patient's cardiac history is questionable, a measurement of left ventricular ejection fraction should be obtained within 42 days prior to registration; patients with left ventricular ejection fraction < 50% are not eligible
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction at rest must be >= 35%
Left ventricular ejection fraction at least 45% on appropriate medical therapy; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricular ejection fraction >= 45%
Left ventricular ejection fraction equal or greater than 40%
Patients with symptomatic coronary artery disease, uncontrolled congestive heart failure; left ventricular ejection fraction is not required to be measured, however if it is measured, patient is excluded if ejection fraction is < 30%
Left ventricular ejection fraction greater than 40%
Left ventricular ejection fraction at rest must be >= 35%
Left ventricular ejection fraction > 50%
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction >= 45%
Has Left Ventricular Ejection Fraction ? 50%
Left ventricular ejection fraction greater than 45%
Ventricular ejection fraction (VEF) =< 55% at baseline
Stable cardiac condition with a left ventricular ejection fraction of 40% or greater.
Left ventricular ejection fraction > 45%
Known history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmias
Left ventricular ejection fraction less than 50%
Left ventricular ejection fraction at rest > 40% within 3 months of registration.
Left ventricular ejection fraction >= 50% OR
Left ventricular ejection fraction >= 45%
Left ventricular ejection fraction > 40% (within 28 days of treatment start)
Left ventricular ejection fraction at rest >= 40%
Patients with a left ventricular ejection fraction of < 45%
Patients with a left ventricular ejection fraction of < 45%
Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
Left ventricular ejection fraction > 40% estimated
Left ventricular function 40% or greater
All subjects must have left ventricular ejection fraction ?50%.
Left ventricular ejection fraction < 45%
Left ventricular ejection fraction at rest > 40% within 3 months of registration
Participant's left ventricular ejection fraction is within normal institutional ranges
Left ventricular ejection fraction < 50%.
Left ventricular ejection fraction (LEF) >= 40%
Ventricular ejection fraction >= 40%
Left ventricular ejection fraction >= 45%
Left ventricular ejection fraction >= 50%
Left ventricular ejection fraction < 45% in patients with prior anthracycline use or otherwise at risk for left ventricular systolic dysfunction
Resting left ventricular ejection fraction <50% at the time of screening
Reduced left ventricular ejection fraction (< 50%) or other evidence of cardiac dysfunction as determined by the investigator
Left ventricular ejection fraction > 45% OR
Cardiac disease with left ventricular ejection fraction of less than 45%
Left ventricular ejection fraction at least 40%
Left ventricular ejection fraction of at least 40%
Patients with a ventricular ejection fraction (=< 30%), or respiratory compromise (FEV1 =< 40%)
Left ventricular ejection fraction < 35%
Left ventricular ejection function < 45%
Left ventricular ejection fraction < 50% by ECHO
Cardiac function - left ventricular ejection fraction >= 40%
Left ventricular ejection fraction < 35%
Patients who are receiving trastuzumab must have a left ventricular ejection fraction of >= 50%
Left ventricular ejection fraction < 50%
The patient has a left ventricular ejection fraction of < 40%
Left ventricular ejection fraction equal or greater than 40%
Patients must have left-ventricular ejection fraction > 50% at baseline
No symptoms of uncontrolled cardiac disease, left ventricular ejection fraction >= 40%
Suboptimal cardiac function as defined by decreased left ventricular ejection fraction < 55% for cohort 1, and < 50% for cohort 2
Left ventricular ejection fraction of at least 40-45%
Known history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmias
Normal estimated left ventricular ejection fraction and no history of ischemic heart disease requiring revascularization, unless cleared by a cardiologist
Left ventricular ejection fraction >= 40%
Left ventricular ejection fraction < 50%
Left ventricular ejection fraction
Left ventricular ejection fraction < 40 %.
Baseline left ventricular ejection fraction > or = 50%
Left ventricular ejection fraction
Myocardial infarction (MI) within the previous six months, or patients with left ventricular ejection fraction of less than 45% secondary to a more remote MI.
Ventricular ejection fraction (VEF) =< 50 % at baseline
Recipient must have adequate cardiac function with a left ventricular ejection fraction > 40%.
Left ventricular ejection fraction > 50% or the institutional LLN within 28 days prior to the first dose of study treatment.
Left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
Left ventricular ejection fraction >= 40%
Left ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricular ejection fraction of > 40%
Subject has a left ventricular ejection fraction ?45%.
Normal cardiac function (left ventricular ejection fraction >= 50%)
Normal cardiac function (left ventricular ejection fraction >= 50%)
Left ventricular ejection fraction > 35%
Left ventricular ejection fraction > 40%